Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: Low-burst release is crucial for efficient CD8+ T cell activation

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 83, Issue 3, 2013, Pages 338-345

  Silva, A L ^a   Rosalia, R A ^b   Sazak, A ^a   Carstens, M G ^a   Ossendorp, F ^b   Oostendorp, J ^b   Jiskoot, W ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer immunotherapy; Cellular immune response; CTL epitope; Peptide antigen; PLGA nanoparticles

Indexed keywords

CD8 ANTIGEN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NANOPARTICLE; OVALBUMIN; OVALBUMIN 24; POLYGLACTIN; SOLVENT; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG FORMULATION; EMULSION; ENCAPSULATION; EVAPORATION; IN VITRO STUDY; PARTICLE SIZE; PH; SUSPENSION; T LYMPHOCYTE ACTIVATION; ZETA POTENTIAL;

AMINO ACID SEQUENCE; CD8-POSITIVE T-LYMPHOCYTES; LACTIC ACID; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; NANOPARTICLES; PEPTIDES; POLYGLYCOLIC ACID;

EID: 84875211421     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.11.006     Document Type: Article

References (61)

1. Y. Perrie, A.R. Mohammed, D.J. Kirby, S.E. McNeil, and V.W. Bramwell Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens Int. J. Pharm. 364 2008 272 280
2. C.J. Melief, and S.H. van der Burg Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines Nat. Rev. Cancer 8 2008 351 360
3. R. Steinman, and K. Inaba Immunogenicity: role of dendritic cells Bioessays 10 1989 145 152
4. R.M. Steinman The dendritic cell system and its role in immunogenicity Annu. Rev. Immunol. 9 1991 271 296
5. + cytotoxic T lymphocytes by dendritic cells J. Exp. Med. 166 1987 182 194
6. C. Trumpfheller, M.P. Longhi, M. Caskey, J. Idoyaga, L. Bozzacco, T. Keler, S.J. Schlesinger, and R.M. Steinman Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity J. Int. Med. 271 2012 183 192
7. A. Vulink, K.J. Radford, C. Melief, and D.N. Hart Dendritic cells in cancer immunotherapy Adv. Cancer Res. 99 2008 363 407
8. C.J. Melief Cancer immunotherapy by dendritic cells Immunity 29 2008 372 383
9. S. Zwaveling, S.C. Ferreira Mota, J. Nouta, M. Johnson, G.B. Lipford, R. Offringa, S.H. van der Burg, and C.J. Melief Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides J. Immunol. 169 2002 350 358
10. F. Ossendorp, E. Mengede, M. Camps, R. Filius, and C.J. Melief Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors J. Exp. Med. 187 1998 693 702
11. + T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine Clin. Cancer Res. 14 2008 178 187
12. G.G. Kenter, M.J. Welters, A.R. Valentijn, M.J. Lowik, D.M. Berends-van der Meer, A.P. Vloon, J.W. Drijfhout, A.R. Wafelman, J. Oostendorp, G.J. Fleuren, R. Offringa, S.H. van der Burg, and C.J. Melief Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity Clin. Cancer Res. 14 2008 169 177
13. G.G. Kenter, M.J. Welters, A.R. Valentijn, M.J. Lowik, D.M. Berends-van der Meer, A.P. Vloon, F. Essahsah, L.M. Fathers, R. Offringa, J.W. Drijfhout, A.R. Wafelman, J. Oostendorp, G.J. Fleuren, S.H. van der Burg, and C.J. Melief Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia N. Engl. J. Med. 361 2009 1838 1847
14. C.J. Melief Synthetic vaccine for the treatment of lesions caused by high risk human papilloma virus Cancer J. 17 2011 300 301
15. C.J. Melief Treatment of established lesions caused by high-risk human papilloma virus using a synthetic vaccine J. Immunother. 35 2012 215 216
16. C.L. Chiang, L.E. Kandalaft, and G. Coukos Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines Int. Rev. Immunol. 30 2011 150 182
17. W.J. van Driel, M.E. Ressing, G.G. Kenter, R.M. Brandt, E.J. Krul, A.B. van Rossum, E. Schuuring, R. Offringa, T. Bauknecht, A. Tamm-Hermelink, P.A. van Dam, G.J. Fleuren, W.M. Kast, C.J. Melief, and J.B. Trimbos Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phases I-II trial Eur. J. Cancer 35 1999 946 952
18. C.L. Slingluff Jr., G. Yamshchikov, P. Neese, H. Galavotti, S. Eastham, V.H. Engelhard, D. Kittlesen, D. Deacon, S. Hibbitts, W.W. Grosh, G. Petroni, R. Cohen, C. Wiernasz, J.W. Patterson, B.P. Conway, and W.G. Ross Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes Clin. Cancer Res. 7 2001 3012 3024
19. J. Aucouturier, S. Ascarateil, and L. Dupuis The use of oil adjuvants in therapeutic vaccines Vaccine 24 Suppl. 2 2006 S244 S245
20. J. Aucouturier, L. Dupuis, S. Deville, S. Ascarateil, and V. Ganne Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines Expert Rev. Vaccines 1 2002 111 118
21. P.P. Leenaars, M.A. Koedam, P.W. Wester, V. Baumans, E. Claassen, and C.F. Hendriksen Assessment of side effects induced by injection of different adjuvant/antigen combinations in rabbits and mice Lab. Anim. 32 1998 387 406
22. C.E. Astete, and C.M. Sabliov Synthesis and characterization of PLGA nanoparticles J. Biomater. Sci. Polym. Ed. 17 2006 247 289
23. L.J. Cruz, P.J. Tacken, R. Fokkink, B. Joosten, M.C. Stuart, F. Albericio, R. Torensma, and C.G. Figdor Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro J. Controlled Release 144 2010 118 126
24. S. Fischer, E. Schlosser, M. Mueller, N. Csaba, H.P. Merkle, M. Groettrup, and B. Gander Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response J. Drug Target 17 2009 652 661
25. R.C. Mundargi, V.R. Babu, V. Rangaswamy, P. Patel, and T.M. Aminabhavi Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives J. Control Release 125 2008 193 209
26. P. Vlieghe, V. Lisowski, J. Martinez, and M. Khrestchatisky Synthetic therapeutic peptides: science and market Drug Discov. Today 15 2010 40 56
27. J.F. Woodley Enzymatic barriers for GI peptide and protein delivery Crit. Rev. Ther. Drug Carrier Syst. 11 1994 61 95
28. N. Schall, N. Page, C. Macri, O. Chaloin, J.P. Briand, and S. Muller Peptide-based approaches to treat lupus and other autoimmune diseases J. Autoimmun. 2012
29. K.A. Witt, T.J. Gillespie, J.D. Huber, R.D. Egleton, and T.P. Davis Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability Peptides 22 2001 2329 2343
30. M.L. De Temmerman, J. Rejman, J. Demeester, D.J. Irvine, B. Gander, and S.C. De Smedt Particulate vaccines: on the quest for optimal delivery and immune response Drug Discov. Today 16 2011 569 582
31. T.M. Fahmy, S.L. Demento, M.J. Caplan, I. Mellman, and W.M. Saltzman Design opportunities for actively targeted nanoparticle vaccines Nanomedicine (Lond) 3 2008 343 355
32. P. Elamanchili, C.M. Lutsiak, S. Hamdy, M. Diwan, and J. Samuel "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells J. Immunother. 30 2007 378 395
33. E. Schlosser, M. Mueller, S. Fischer, S. Basta, D.H. Busch, B. Gander, and M. Groettrup TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses Vaccine 26 2008 1626 1637
34. S. Jain, D.T. O'Hagan, and M. Singh The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant Expert Rev. Vaccines 10 2011 1731 1742
35. I.M. van der Lubben, J.C. Verhoef, G. Borchard, and H.E. Junginger Chitosan and its derivatives in mucosal drug and vaccine delivery Eur. J. Pharm. Sci. 14 2001 201 207
36. W. Jiang, R.K. Gupta, M.C. Deshpande, and S.P. Schwendeman Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens Adv. Drug Deliv. Rev. 57 2005 391 410
37. E. Mata, M. Igartua, R.M. Hernandez, J.E. Rosas, M.E. Patarroyo, and J.L. Pedraz Comparison of the adjuvanticity of two different delivery systems on the induction of humoral and cellular responses to synthetic peptides Drug Deliv. 17 2010 490 499
38. B. Slutter, L. Plapied, V. Fievez, M.A. Sande, A. des Rieux, Y.J. Schneider, E. Van Riet, W. Jiskoot, and V. Preat Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination J. Control Release 138 2009 113 121
39. A. Yang, L. Yang, W. Liu, Z. Li, H. Xu, and X. Yang Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: preparation and in vitro evaluation Int. J. Pharm. 331 2007 123 132
40. C. Wischke, and S.P. Schwendeman Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles Int. J. Pharm. 364 2008 298 327
41. M. Mueller, E. Schlosser, B. Gander, and M. Groettrup Tumor eradication by immunotherapy with biodegradable PLGA microspheres-an alternative to incomplete Freund's adjuvant Int. J. Cancer 129 2011 407 416
42. Y. Liu, and S.P. Schwendeman Mapping microclimate pH distribution inside protein-encapsulated PLGA microspheres using confocal laser scanning microscopy Mol. Pharm. 9 2012 1342 1350
43. M. van de Weert, W.E. Hennink, and W. Jiskoot Protein instability in poly(lactic-co-glycolic acid) microparticles Pharm. Res. 17 2000 1159 1167
44. W. Jiskoot, T.W. Randolph, D.B. Volkin, C.R. Middaugh, C. Schoneich, G. Winter, W. Friess, D.J. Crommelin, and J.F. Carpenter Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release J. Pharm. Sci. 101 2012 946 954
45. + CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity J. Immunol. 179 2007 5033 5040
46. S. Khan, M.S. Bijker, J.J. Weterings, H.J. Tanke, G.J. Adema, T. van Hall, J.W. Drijfhout, C.J. Melief, H.S. Overkleeft, G.A. van der Marel, D.V. Filippov, S.H. van der Burg, and F. Ossendorp Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells J. Biol. Chem. 282 2007 21145 21159
47. B. Slutter, S. Bal, C. Keijzer, R. Mallants, N. Hagenaars, I. Que, E. Kaijzel, W. van Eden, P. Augustijns, C. Lowik, J. Bouwstra, F. Broere, and W. Jiskoot Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen Vaccine 28 2010 6282 6291
48. C. Winzler, P. Rovere, M. Rescigno, F. Granucci, G. Penna, L. Adorini, V.S. Zimmermann, J. Davoust, and P. Ricciardi-Castagnoli Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures J. Exp. Med. 185 1997 317 328
49. S. Sanderson, and N. Shastri LacZ inducible, antigen/MHC-specific T cell hybrids Int. Immunol. 6 1994 369 376
50. A. Wieber, T. Selzer, and J. Kreuter Characterisation and stability studies of a hydrophilic decapeptide in different adjuvant drug delivery systems: a comparative study of PLGA nanoparticles versus chitosan-dextran sulphate microparticles versus DOTAP-liposomes Int. J. Pharm. 421 2011 151 159
51. X. Luan, and R. Bodmeier Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems J. Controlled Release 110 2006 266 272
52. W. Bao, J. Zhou, J. Luo, and D. Wu PLGA microspheres with high drug loading and high encapsulation efficiency prepared by a novel solvent evaporation technique J. Microencapsulation 23 2006 471 479
53. E. Gasteiger, A. Gattiker, C. Hoogland, I. Ivanyi, R.D. Appel, and A. Bairoch ExPASy: the proteomics server for in-depth protein knowledge and analysis Nucleic Acids Res. 31 2003 3784 3788
54. J. Kyte, and R.F. Doolittle A simple method for displaying the hydropathic character of a protein J. Mol. Biol. 157 1982 105 132
55. T. Jung, W. Kamm, A. Breitenbach, G. Klebe, and T. Kissel Loading of tetanus toxoid to biodegradable nanoparticles from branched poly(sulfobutyl- polyvinyl alcohol)-g-(lactide-co-glycolide) nanoparticles by protein adsorption: a mechanistic study Pharm. Res. 19 2002 1105 1113
56. P.A. Sales-Junior, F. Guzman, M.I. Vargas, S. Sossai, V.A. Patarroyo, C.Z. Gonzalez, and J.H. Patarroyo Use of biodegradable PLGA microspheres as a slow release delivery system for the Boophilus microplus synthetic vaccine SBm7462 Vet. Immunol. Immunopathol. 107 2005 281 290
57. M. Rafi, S.M. Singh, V. Kanchan, C.K. Anish, and A.K. Panda Controlled release of bioactive recombinant human growth hormone from PLGA microparticles J. Microencapsulation 27 2010 552 560
58. K.W. Burton, M. Shameem, B.C. Thanoo, and P.P. DeLuca Extended release peptide delivery systems through the use of PLGA microsphere combinations J. Biomater. Sci. Polym. Ed. 11 2000 715 729
59. B. Buyuktimkin, Q. Wang, P. Kiptoo, J.M. Stewart, C. Berkland, and T.J. Siahaan Vaccine-like controlled-release delivery of an immunomodulating peptide to treat experimental autoimmune encephalomyelitis Mol. Pharm. 9 2012 979 985
60. J. Yang, H. Sun, and C. Song Preparation, characterization and in vivo evaluation of pH-sensitive oral insulin-loaded poly(lactic-co-glycolicacid) nanoparticles Diabetes Obes. Metab. 14 2012 358 364
61. N. van Montfoort, M.G. Camps, S. Khan, D.V. Filippov, J.J. Weterings, J.M. Griffith, H.J. Geuze, T. van Hall, J.S. Verbeek, C.J. Melief, and F. Ossendorp Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity Proc. Natl. Acad. Sci. USA 106 2009 6730 6735